The headline trial: ESSENCE
ESSENCE (Semaglutide in Non-Cirrhotic, Non-Alcoholic Steatohepatitis with Fibrosis)
Sanyal et al., New England Journal of Medicine, April 2025. SYNERGY-NASH (tirzepatide): Loomba et al., NEJM June 2024.
ESSENCE: semaglutide 2.4 mg weekly led to resolution of steatohepatitis without worsening of fibrosis in 62.9 percent of patients versus 34.3 percent on placebo at week 72. Fibrosis improvement without worsening of MASH occurred in 36.8 percent versus 22.4 percent. SYNERGY-NASH: tirzepatide 10 mg achieved MASH resolution in approximately 62 percent of patients at week 52 versus 10 percent on placebo.
Trial enrollment criteria
- Biopsy-confirmed MASH with fibrosis stage F2 or F3 (non-cirrhotic)
- NAS (NAFLD Activity Score) of at least 4
- BMI greater than or equal to 30 (most patients) or relevant comorbidity
- Stable metabolic profile, no decompensated cirrhosis
Does this trial apply to you?
MASH diagnosis typically requires liver biopsy or, increasingly, validated non-invasive markers (FibroScan + FAST score, MEFIB score or MRE). If you have biopsy-confirmed MASH with F2 or F3 fibrosis, semaglutide 2.4 mg has FDA approval for this indication as of 2025. Earlier-stage MASLD without significant fibrosis is not currently an FDA-labeled indication but is often qualifying under obesity-with-comorbidity.
What to ask your prescriber
- Whether your liver fibrosis stage has been confirmed (biopsy, MRE or FibroScan + FAST)
- Most recent ALT, AST, GGT and FibroScan readings
- Whether the MASH indication or the obesity-with-comorbidity indication is the cleaner PA path
- Whether you should see a hepatologist before starting GLP-1 if you have any cirrhosis risk
Editorial notes
- If you have decompensated cirrhosis (Child-Pugh C, history of variceal bleed or hepatic encephalopathy), GLP-1 RA is generally NOT recommended and should be discussed with hepatology before any initiation.
- MASH coverage under commercial plans is still patchwork in 2026; expect more PAs to be denied than approved in the first year. The obesity-with-comorbidity path remains the cleaner route for most patients.
- Pair with hepatology follow-up at 6 months on the first cycle to confirm liver-enzyme trajectory.
Clinical trials for Metabolic dysfunction-associated steatohepatitis (MASH/MASLD)
Or browse the full GLP-1 clinical trials directory, filterable by condition, state and phase.
Take it to your prescriber: PA letter templates
Editable prior-authorization letter templates that cite the registration trial above. Pick the plan your prescriber will submit to, copy the template, fill in the patient-specific findings and have your clinician sign and submit.
Not seeing your plan? The full PA letter librarycovers 20 plans × 10 indications = 200 templates. The appeal letter library handles denials.
Drug profiles
Other GLP-1 conditions
Editorial provenance
Editorial review by John, Editor on 2026-05-23, against ESSENCE (Sanyal et al., New England Journal of Medicine, April 2025. SYNERGY-NASH (tirzepatide): Loomba et al., NEJM June 2024.). We do not yet have a credentialed medical reviewer on staff (actively recruiting). This page summarises public registration-trial data and FDA labeling. It is not clinician-authored medical advice.
Disclaimer
Educational summary of published registration trial data. Not medical advice. Not a substitute for evaluation by a treating clinician. Trial-level results do not guarantee individual outcomes. Discuss eligibility, contraindications, dose adjustments and drug interactions with your prescriber. We do not have a credentialed medical reviewer on staff yet (actively recruiting); the content below is editor-written from public registration-trial publications and FDA labeling, not clinician-authored medical advice.